This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crowell, J. A. Articles by Fay, J. R. Search for Related Content PubMed PubMed Citation Articles by Crowell, J. A. Articles by Fay, J. R. Related Collections Epidemiology and Prevention Epidemiology and Prevention: Chemoprevention

Minireview

Is Inducible Nitric Oxide Synthase a Target for Chemoprevention?

National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent Development Research Group, Bethesda, Maryland 20892 [J. A. C., V. E. S.] and CCS Associates, Mountain View, California 94043 [C. C. S., J. R. F.]

¹ To whom requests for reprints should be addressed, at National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent Development Research Group, Executive Plaza North, Room 2117, 9000 Rockville Pike, Bethesda, MD 20892. Phone: (301) 594-0459; Fax: (301) 402-0553; E-mail: jcrowell{at}mail.nih.gov

The molecular messenger nitric oxide (NO) is synthesized endogenously from L-arginine by three isoforms of the enzyme NO synthase. The isoform most consistently associated with neoplasia is the inducible form, inducible nitric oxide synthase (iNOS). However, the role played by the NO/iNOS system in tumor development is complex, and both promoting and inhibitory effects on neoplasia have been reported. This review attempts to clarify the role of iNOS in carcinogenesis, with particular emphasis on the early stages of tumor development, offers possible explanations for the confused picture presented in the literature regarding the association of the NO/iNOS pathway with neoplasia, and identifies selective iNOS inhibitors that may have chemopreventive potential.

This article has been cited by other articles:

				K. Engels, S. K. Knauer, S. Loibl, V. Fetz, P. Harter, A. Schweitzer, A. Fisseler-Eckhoff, F. Kommoss, L. Hanker, V. Nekljudova, et al. NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas Cancer Res., July 1, 2008; 68(13): 5159 - 5166. [Abstract] [Full Text] [PDF]

				L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340. [Abstract] [Full Text] [PDF]

				Q. Du, K. S. Park, Z. Guo, P. He, M. Nagashima, L. Shao, R. Sahai, D. A. Geller, and S. P. Hussain Regulation of Human Nitric Oxide Synthase 2 Expression by Wnt {beta}-Catenin Signaling. Cancer Res., July 15, 2006; 66(14): 7024 - 7031. [Abstract] [Full Text] [PDF]

				A. J. Pantuck, J. T. Leppert, N. Zomorodian, W. Aronson, J. Hong, R. J. Barnard, N. Seeram, H. Liker, H. Wang, R. Elashoff, et al. Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 4018 - 4026. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				S. H. Itzkowitz and X. Yio Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G7 - G17. [Abstract] [Full Text] [PDF]